The report demonstrates why urgent congressional action is needed to address Big Pharma’s abusive pricing practices.
"Patients are counting on Congress and the Biden administration to deliver drug pricing reforms immediately in this new year."
PRESS CONFERENCE: P4AD’s David Mitchell Says House Oversight Committee Report Drives Home Need For Swift Senate Passage Of BBB To Reform Broken Drug Pricing System
The Build Back Better Act “Will Make Our System Work Better For Those It Is Intended To Serve: Patients And All Americans”
Government And Taxpayers Saved The Day; Drug Corporations Did Their Job, Then Cashed In
RELEASE: Setting The Record Straight — New Fact Check Exposes Big Pharma’s Lies About Medicare Negotiation
Patients For Affordable Drugs Responds To The Industry’s $18 Million Attack Ads Aimed At Thwarting Reforms To Lower Drug Prices
STATEMENT: P4AD Applauds FDA’s Approval Of First Interchangeable Biosimilar Insulin, Calls For Affordable Insulin For All
The FDA’s approval of Semglee as an interchangeable biosimilar to Lantus is an important step forward on the road to real competition.